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Abstract 
Cardiovascular and metabolic diseases remain the leading cause of morbidity and mortality 
worldwide. Endothelial dysfunction is a key player in the initiation and progression of 
cardiovascular and metabolic diseases. Current evidence suggests that the anti-diabetic drug 
metformin improves insulin resistance and protects against endothelial dysfunction in the 
vasculature. Hereby, we provide a timely review on the protective effects and molecular 
mechanisms of metformin in preventing endothelial dysfunction and cardiovascular and 
metabolic diseases. 
Keywords : Metformin, mechanism of action, endothelium, hyperglycaemia, CVD, 
endothelial dysfunction 
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Abbreviations 
AGE advanced glycation end-products 
AngII Angiotensin II 
AJ adherens junctions 
Bcl6 B-cell lymphoma 6  
BH4 tetrahydrobiopterin 
CVD cardiovascular disease 
cGMP cyclic guanosine 5’ monophosphate 
DHAP dihydroxy acetone phosphate 
ED endothelial dysfunction 
EDHF endothelium derived hyperpolarizing factor 
EDRF endothelium- derived relaxing factor 
eNOS endothelial nitric oxide synthase 
ER endoplasmic reticulum 
ET-1 endothelin-1 
eNOS endothelial nitric oxide synthase 
FAD flavin adenine dinucleotide 
FMN flavin adenine mononucleotide 
G6PDH glucose-6-phosphatese dehydrogenase  
GAPDH glyceraldehyde phosphate dehydrogenase 
GCH1 GTP cyclohydrolase I 
GTPCH1 guanosine 5’-triphosphate cyclohydrolase 1 
H2S hydrogen sulphide 
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HSP90 heat shock protein 90 
HUVECS human umbilical vein endothelial cells 
ICAM1 intracellular adhesion molecule 1; 
LOX-1 lectin-like oxidized LDL receptor 1 
MAPK mitogen activated protein kinase 
Mn-SOD manganese superoxide dismutase 
MCP1 monocyte chemo attractant protein 1; 
mTOR mammalian target of rapamycin 
mPTP mitochondrial permeability transition pore 
NF-kB nuclear factor kappa B; 
NO nitric oxide 
NOX NADPH oxidase 
PAI-1 plasminogen activator 1  
PAPP1 p, phosphorylation of poly-ADP-ribose polymerase 1 
PEPCK phosphoenolpyruvate carboxykinase 
PCOS polycystic ovary syndrome 
PPARδ peroxisome proliferator-activated receptor δ 
PGI2 prostacyclin I2 
PGC1α PPARgamma Coactivator 1alpha 
PKC protein kinase C 
ROS reactive oxygen species 
TJ tight junctions 
t-PA tissue type plasminogen activator 
TNFα Tumour necrosis factor - alpha 
TRAF3IP2 TRAF3 interacting protein 2 
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Sirt1 Sirtuin 1 
u-PA urokinase plasminogen activator 
VCAM1 vascular adhesion molecule 1 
VEGF vascular endothelial growth factor 
VSMCs vascular smooth muscle cells 
vWF von willebrand factor  
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1. Introduction 
Cardiovascular disease (CVD) is the largest cause of morbidity and mortality in modern 
societies (Fang, Little, & Xu, 2017; Writing Group, et al., 2016). The major underlying 
pathology of CVD is atherosclerosis (Libby, 2006; Little, Osman, & O'Brien, 2008; Ross, 
1986; Tabas, Williams, & Boren, 2007). Atherosclerosis is accelerated by the diabetic milieu 
but the mechanisms of this response are unclear. The impact of drugs which reverse the 
diabetic state on preventing atherosclerosis and CVD is also controversial (Nigro, Osman, 
Dart, & Little, 2006; S. N. Yang, et al., 2010). The phenomena of endothelial dysfunction 
(ED) is closely associated with atherosclerosis. In this context, it is important to have a full 
understanding of the action of drugs which treat the diabetic state and impact on ED for a full 
appreciation of their potential role in reducing the development and progression of 
atherosclerosis and hence CVD.  
There are many risk factors for CVD most prominently hypertension, hyperglycaemia 
and hyperlipidaemia which are modifiable by medical treatment. Risk factors are not of 
concern in their own role but for their role in accelerating the onset or rate of development of 
atherosclerosis. CVD in diabetes is traditionally divided into the microvascular diseases of 
small vessels and the macrovascular disease of larger vessels where hyperglycaemia is the 
cause of the former and it is closely associated with the latter.  
Type 2 diabetes is now recognised as an important risk factor for CVD and in patients 
with diabetes but without a previous cardiovascular event Type 2 diabetes carries a similar 
risk of a future event to a subject without diabetes who has had a previous event (Haffner, 
1997). The principal metabolic abnormalities of diabetes are insulin resistance, pancreatic 
beta cell failure and abnormalities of the incretin system where early Type 2 diabetes is 
characterized by insulin resistance and rising plasma insulin (relative insulin deficiency) and 
in the later stages beta cell failure leads to an absolute deficiency of insulin and 
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hyperglycaemia. Incretins impact on these two parameters and can modify the progression of 
disease and also serve as therapeutic targets (Cernea, 2011). 
To be truly efficacious, lowering of risk factors for CVD must have effects on lowering 
cardiovascular events and increase life expectancy. Medical treatments are often assessed for 
their acute or short-term effects on risk factors but it is the ultimate outcomes on CVD that 
are important. Therapeutic agents that are highly effective in reducing risk factors but this 
may not always be sufficient to reduce the incidence of CVD. The action on risk factors may 
be counteracted by their deleterious effects on the cardiovascular system such as occurred for 
COX inhibitors (Fanelli, Ghisi, Aprile, & Lapi, 2017). Therefore, preferably agents should 
have range of effects, known as pleiotropic effects directly on the cardiovascular system so 
that these effects can work in tandem with the risk factor benefit to get an overall reduction in 
CVD and mortality.  
In Type 2 diabetes, it has been extremely difficult to discover agents which can reduce 
hyperglycaemia and reduce cardiovascular events safely. Indeed, most agents for the 
treatment of diabetes have not attained these criteria of efficacy and safety. One old agent 
which had a mixed early therapeutic history is the biguanide, metformin. Metformin has 
recently risen to the top of the relevant therapeutic armamentarium tree to become the first 
line medical therapy for the treatment of the hyperglycaemia accompanying Type 2 diabetes 
(Gray, McGuire, Cohen, & Little, 2017; Stumvoll, Nurjhan, Perriello, Dailey, & Gerich, 
1995). As mentioned above, ED is thought to accelerate the development and progression of 
atherosclerosis and accordingly targeting and reducing ED is hypothesized to reduce CVD. 
The overall effect of metformin appears to be a reduction in cardiovascular events but the 
topic is of some debate (UK Prospective Diabetes Study (UKPDS) Group, 1998). 
Understanding the effects of metformin on ED would advance our understanding of the full 
therapeutic potential of metformin. The effects of metformin, as other risk factor addressing 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
agents, arise from its primary effect on the risk factors (insulin resistance and 
hyperglycaemia) and its associated direct effects on the vasculature, indeed the endothelium. 
In this review, we address the use of metformin in diabetes and associated vascular 
complications, and analyse the effects of metformin on the endothelium due to its anti-
hyperglycaemic and vasculoprotective actions. In these days of personalized medicine, a deep 
understanding of effects of therapeutic agents may point to populations in which the balance 
of unwanted and favourable effects is tipped in the desired direction and the use of drugs can 
be optimised. Here we analyse the actions of metformin with a view to seeking optimum 
patient outcomes for people treated with this ubiquitous agent. 
 2. Endothelial function and dysfunction 
The endothelium is a single layer of cells which separates all tissues from circulating 
blood (A Chistiakov, V Revin, A Sobenin, N Orekhov, & V Bobryshev, 2015; Minami & 
Aird, 2005). Intact endothelium acts in an autocrine, paracrine and endocrine manner and 
secretes a number of bioactive mediators that affect vascular tone (Muniyappa & Sowers, 
2013). A seminal experiment by Robert Furchgott and colleagues  (Furchgott & Zawadzki, 
1980) demonstrated that removal of endothelium from isolated arteries prevents the ex vivo 
vasodilatory response to acetylcholine; indeed denuded vessels constrict in response to 
acetylcholine. Subsequently it was revealed that acetylcholine stimulates the endothelium to 
release endothelium-derived relaxing factor (EDRF) which was later characterized as the 
vasoactive gas, nitric oxide (NO) (Ignarro, Buga, Wood, Byrns, & Chaudhuri, 1987). Healthy 
endothelium maintains a low level of oxidative stress and a relaxed vascular tone by releasing 
several vasoactive mediators. Major vasodilators released by endothelial cells include NO, 
prostacyclin I2 (PGI2) endothelium derived hyperpolarizing factor (EDHF), bradykinin, 
histamine, serotonin, substance P while the key secreted vasoconstrictors include endothelin-
1 (ET-1), angiotensin II (ANG-II), thromboxane A2, prostacyclin H2 and reactive oxygen 
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species (ROS) (Endemann & Schiffrin, 2004; Just, Whitten, & Arendshorst, 2008; Lai & 
Kan, 2015; Moncada, Gryglewski, Bunting, & Vane, 1976; R MoJ Palmer, Ferrige, & 
Moncada, 1987; Yanagisawa, et al., 1988). The delicate balance between this plethora of 
vasodilators and vasoconstrictors and pro- and anti-coagulation factors is crucial for 
physiological functioning of the endothelium and an imbalanced production of these 
molecules leads to failed vascular auto regulation and influences the structural and functional 
integrity of the endothelium with pathophysiological consequences (Ghosh, Gao, Thakur, 
Siu, & Lai, 2017). 
3. Endothelial Dysfunction 
 The functional integrity of endothelium is important to vascular health. Imbalance 
between vasodilators and vasoconstrictors as well as chronic disturbances in mechanical 
shear stress caused by dyslipidaemia, hypertension and diabetes leads to endothelial 
dysfunction. Endothelial dysfunction is not only an initiator but also could be an important 
contributor to the progression of CVD (Barton & Haudenschild, 2001; Endemann & 
Schiffrin, 2004; Félétou & Vanhoutte, 2006a). Endothelial dysfunction is characterised and 
defined by one or more of following features: reduced production and bioavailability of NO, 
impaired endothelium dependent vasorelaxation, impaired fibrinolytic ability, hemodynamic 
dysregulation, enhanced expression of adhesion molecules and inflammatory genes, 
increased generation of ROS and enhanced permeability of vascular endothelium (Ghosh, et 
al., 2017; Gimbrone & García-Cardeña, 2016; Cristina M Sena, Ana M Pereira, & Raquel 
Seiça, 2013). In disease states the endothelium undergoes functional and structural alterations 
and loses its CVD protective role (Versari, Daghini, Virdis, Ghiadoni, & Taddei, 2009). 
Several studies have linked endothelial dysfunction and resultant atherosclerosis to insulin 
resistant states, such as obesity and diabetes (Bakker, Eringa, Sipkema, & van Hinsbergh, 
2009; J.-a. Kim, Montagnani, Koh, & Quon, 2006; Nigro, et al., 2006).  
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4. Regulation of vascular tone 
The endothelium regulates vascular tone by producing and releasing NO, and 
prostacyclin and by hyperpolarising vascular smooth muscle cells  (VSMCs). NO is the major 
vasodilator synthesised by endothelial nitric oxide synthase (eNOS or NOS3) (Nishida, et al., 
1992). NO is synthesized from the oxidation of L-Arginine (Richard MJ Palmer, Ashton, & 
Moncada, 1988), in a twostep process catalysed by eNOS through the generation of N-
hydroxyl-L arginine. eNOS is constitutively expressed in endothelial cells, closely associated 
with caveolae where it binds caveolin-1 that restricts its activity (R MoJ Palmer, et al., 1987). 
Other factors that influence the continuous synthesis of NO by endothelial cells include 
plasma constituents (thrombin, sphingosine1-phosphate), autacoids (bradykinin, histamine, 
prostaglandin), platelet products (adenosine phosphate, serotonin), neurohumoral mediators 
such as acetylcholine and circulating hormones (catecholamines, vasopressin and 
aldosterone) (Michel & Vanhoutte, 2010). Furthermore, mechanical forces regulate eNOS 
gene expression differentially in areas of disturbed flow versus steady laminar flow. 
Endothelial cells exposed to laminar flow possess enhanced NO forming capacity (Chiu & 
Chien, 2011). Once produced, NO readily diffuses to VSMCs and activates soluble guanylate 
cyclase system which in turn results in increased levels of cyclic guanosine-3’, 5 mono 
phosphate (cGMP) and relaxation of VSMC (Rapoport & Murad, 1983). NO also exerts its 
effects by reversible modification of proteins by adding NO group at cysthiol forming S-
nitrosylated proteins (Stamler, et al., 1992). S-Nitrosylation of proteins modulates many 
important physiological processes in the cardiovascular system including cell proliferation, 
apoptosis, ion channel activity, exocytosis, blood flow and systemic oxygen delivery. Apart 
from being a key vasodilator, NO counteracts platelet aggregation, VSMC proliferation and 
leukocyte adhesion to the endothelium (de Graaf, et al., 1992)(Cornwell, Arnold, Boerth, & 
Lincoln, 1994). The endothelium also mediates the hyperpolarization of VSMCs by releasing 
EDHF and directly by intercellular communication through gap junctions. NO and other 
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vasodilators act co-operatively and oppose the action of vasoconstrictors this maintaining the 
normal arterial patency.  
5. Endothelial transmigration by blood borne cells 
Inflammation is a key player in both the development and acute activation of vascular 
cells (Libby, Ridker, & Hansson, 2011). Under physiological conditions, the endothelium 
resists attachment of leukocytes to its surface (Libby, et al., 2011). NO maintains the 
endothelium in a quiescent, anti- inflammatory state and prevents leukocyte adhesion 
(Widlansky, Gokce, Keaney, & Vita, 2003). However, the endothelium shows up regulated 
expression adhesion molecules such as vascular adhesion molecule 1 (VCAM-1) and 
intracellular adhesion molecule 1 (ICAM-1) (Libby, Ridker, & Maseri, 2002) in CVD risk 
factors, such as dyslipidaemia, hypertension and increased proinflammatory mediators. 
Consequently, the endothelium is rendered adhesive for circulating leukocytes,  thereby 
initiating an intriguing multistep process involving capturing, rolling, arrest, crawling (to the 
site of injury) and transmigration through the barrier formed by endothelial cell monolayers 
(Vestweber, 2015). The activated endothelium also expresses chemotactic factors such as 
monocyte chemoattractant protein-1 (MCP-1) and proinflammatory cytokines such as 
macrophage colony-stimulating factor, and tumour necrosis factor–alpha (TNFα) (Libby, et 
al., 2002). Expression of these factors in the endothelium contributes to the development of 
inflammation in the arterial wall and promotes atherogenesis. 
6. The phenomenon of endothelial cell senescence  
The phenomenon of cellular senescence is characterized by cell cycle arrest and pro-
inflammatory gene expression (Rodier & Campisi, 2011). Endothelial senescence occurs in 
vivo and is a major contributor to vascular ageing (Erusalimsky, 2009; J. C. Wang & Bennett, 
2012). Cellular senescence is driven by many factors including, high glucose, ROS, 
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inflammatory cytokines, telomere dysfunction, and ionizing radiation (Kojima, Kunimoto, 
Inoue, & Nakajima, 2012; Minamino, et al., 2002; Rogers, Zhang, Azhar, Luo, & Wei, 2013; 
Valenzuela, et al., 1997; Vasto, et al., 2007). Substantial evidence indicates that 
hyperglycaemia–induced ROS formation and reduced bioavailability of NO promotes DNA 
damage, shortening of telomeres, genomic instability and growth arrest in endothelial cells, 
thus resulting in premature endothelial cell senescence (Hoffmann, et al., 2001; Matsui-Hirai, 
et al., 2011; Ota, et al., 2008; Yokoi, et al., 2006). These phenotypically altered endothelial 
cells are pro- inflammatory, pro-thrombotic and pro-atherosclerotic with diminished antigenic 
and regenerative properties (Erusalimsky, 2009; Testa & Ceriello, 2007) and augmented 
diabetes associated CVD .  
7. Endothelial cell apoptosis in the functioning of the endothelium 
Endothelial cell apoptosis is a crucial process for development of atherosclerosis (Peng, 
et al., 2014). The hyperglycaemia of diabetes can induce apoptosis by one or more of the 
following mechanisms: increased intracellular Ca2+, increased oxidative stress, mitochondrial 
dysfunction, changed intracellular fatty acid metabolism, impaired phosphorylation of protein 
kinase Akt and activation of mitogen activated protein kinase (Isoda, et al., 2006). 
Hyperglycaemia increases Bax protein expression, but does not affect that of Bcl-2. 
Elevated Bax/Bcl-2 ratio activates the cleavage of procaspase3 into active caspase-3 and 
triggers apoptosis in Human Umbilical Vein Endothelial Cells (HUVECS) (Z. Yang, et al., 
2008). Intracellular ROS generation is an important cause of apoptotic cell death and is also 
involved in the development of diabetic vascular disease (T. Yu, Sheu, Robotham, & Yoon, 
2008). Hyperglycaemia induced intracellular ROS activate JNK and p38 pathway and 
triggered subsequent apoptosis in HUVECS (Ho, et al., 2006). ROS accumulation in 
mitochondria is a trigger for the intrinsic death pathway, subsequently leading to apoptosis  
(Goyeneche, Harmon, & Telleria, 2006). There are many pathways involved in activating 
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endothelial cell apoptosis but a common mechanism causing endothelial dysfunction and 
endothelial apoptosis is oxidative stress (Van den Oever, Raterman, Nurmohamed, & Simsek, 
2010) . 
 
8. Biochemical mechanisms associated with endothelial dysfunction in diabetes 
8.1 Insulin resistance and endothelial cell dysfunction  
 
In the diabetic milieu, the metabolic disturbances of insulin resistance, hyperglycaemia 
and excessive circulating free fatty acids induces oxidative stress, low grade inflammation, 
platelet hyperactivity and endothelial dysfunction in the vascular tissues (Cristina M. Sena, 
Ana M. Pereira, & Raquel Seiça, 2013). Insulin resistance is linked with lipotoxicity, 
glucotoxicity and inflammation, which initiates and accelerates atherogenesis and vascular 
disease (Kamato, et al., 2014; Little, et al., 2008; Nigro, et al., 2006; Ouchi, Parker, Lugus, & 
Walsh, 2011; S. N. Yang, et al., 2010). A decade ago we speculated that insulin resistance 
was due to the action of an unknown lipophilic metabolite which attenuated insulin signalling 
and this speculation remains valid to this day (Nigro, et al., 2006). Insulin signal transduction 
occurs through two major and ubiquitous signalling pathways. PI3K is involved in mediating 
the metabolic and hemodynamic effects while the Ras-Raf-mitogen-activated-protein kinase 
(MAPK) pathway mediates gene expression, cell growth and differentiation (Avruch, 1998; 
Nigro, et al., 2006). Under normal physiological conditions, insulin activates the PI3K 
pathway, which phosphorylates eNOS at Serine 1177 site, thereby enhancing NO synthesis 
by endothelial cells (Dimmeler, et al., 1999). In insulin resistant states, this pathway is 
impaired and NO production is diminished. Alternatively, the MAPK pathway evokes the 
synthesis of inflammatory markers PAI-1, ICAM-1, VCAM-1, and E-selectin resulting in 
endothelial dysfunction (Montagnani, et al., 2002; Muniyappa & Sowers, 2013). An 
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imbalance between the PI3K and MAPK pathways provides a strong link between insulin 
resistance and endothelial dysfunction (Hsueh & Quiñones, 2003)(J.-a. Kim, et al., 2006). 
This relationship is accelerated by selective inhibition of insulin signalling to eNOS via PI3K, 
whereas  MAPK signalling to ET-1 is unaltered or increased (Z. Y. Jiang, et al., 1999). 
Endothelial dysfunction due to impaired insulin signalling reduces agonist- induced 
vasodilation and the vascular wall becomes more susceptible to atherosclerosis (Maeno, et 
al., 2012; Rask-Madsen, et al., 2010). Furthermore insulin resistance also stimulates VSMC 
proliferation, migration, and causes excessive release of free fatty acids from adipose tissue, 
which elicits pathogenic gene expression through activation of protein kinase C (PKC) and 
raised oxidative stress (Hajer, van Haeften, & Visseren, 2008). 
8.2 Hyperglycaemia and endothelial dysfunction 
Hyperglycaemia is an important factor in endothelial dysfunction and several theories 
have been proposed to explain its adverse effects on the endothelium. These include the 
advanced glycation end product hypothesis, hexosamine hypothesis, aldose reductase  
hypothesis, the hyperperfusion hypothesis, PKC hypothesis and the oxidative stress 
hypothesis (Giacco & Brownlee, 2010).  These hypotheses have overlapping points that 
potentiate each other but oxidative stress is most likely the common disturbance of 
hyperglycaemia (Brownlee, 2001; Van den Oever, et al., 2010). ROS reduces glucose 
metabolism via glycolysis, alternatively, there is increased flux through the hexosamine and 
polyol pathways. Hyperglycaemia induced oxidative stress, causes DNA damage and 
activates nuclear poly (ADP-ribose) polymerase which results in enhanced production of 
polymers of ADP–ribose (PAR). Subsequently, these polymers of ADP-ribose cause 
modification and inactivation of glyceraldehyde phosphate dehydrogenase (GAPDH) (X. Du, 
et al., 2003; Giacco & Brownlee, 2010). Ultimately, the accumulation of  upstream glycolytic 
intermediates glycraldehyde-3-phosphate and dihydroxy acetone phosphate (DHAP), which 
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can be converted to diacylglycerol, activates classical and novel PKC pathways (Way, Katai, 
& King, 2001) . There are at least 11 PKC isoforms and PKCβ is most frequently the 
activated form in vascular cells. The pathogenic consequences of PKC activation include 
dysregulated blood flow due to diminished eNOS activity and increased ET-1 synthesis and 
(S. Chen, Apostolova, Cherian, & Chakrabarti, 2000), impaired vascular permeability in 
VSMC due to induction of vascular endothelial growth factor (Williams, Gallacher, Patel, & 
Orme, 1997), thickening of basement membranes through TGF-β mediated increased 
synthesis of collagen IV and fibronectin, increased plasminogen activator inhibitor -1 (PAI-1) 
expression which impairs fibrinolysis and activation of NADPH oxidase as well as increased 
expression of superoxide producing uncoupled eNOS thus further increasing oxidative stress.  
Glucotoxicity induces a low grade pro-inflammatory state due to activation of 
transcription factors such as nuclear factor kappa B (NF-κB), a key regulator of pro-
atherosclerotic and pro-inflammatory gene targets in VSMC, endothelial cells and 
macrophages (Avogaro, de Kreutzenberg, & Fadini, 2008; Brownlee, 2005; Creager, 
Lüscher, Cosentino, & Beckman, 2003; Little, Chait, & Bobik, 2011). Endothelial cells 
exposed to hyperglycaemic culture media show enhanced NF-κB activation with reduced NO 
production, leukocyte recruitment and inflammatory gene expression (Ding, Vaziri, Coulson, 
Kamanna, & Roh, 2000; X. L. Du, et al., 2001; Esposito, et al., 2001; Luppi, Cifarelli, Tse, 
Piganelli, & Trucco, 2008; Piconi, et al., 2004; Piga, Naito, Kokura, Handa, & Yoshikawa, 
2007).  
8.3 Advanced Glycation End Products (AGEs) and endothelial dysfunction 
 
 Hyperglycaemia promotes non-enzymatic glycation of intracellular and extracellular 
proteins, culminating in the formation of AGEs which subsequently accumulate in the 
vascular wall and decrease NO activity and eNOS expression and increase the expression of 
ET-1 (Avogaro, et al., 2008; Ballinger, et al., 2005; Quehenberger, et al., 2000; Soldatos, 
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Cooper, & Jandeleit-Dahm, 2005). Modification of extracellular proteins, e.g. laminin and 
collagen, increase fluid filtration and decreases vessel elasticity (Huijberts, et al., 1993). AGE 
modification of intracellular and extracellular proteins affects their functions and receptor 
binding properties. Binding of AGEs to their receptors (RAGE) increases intracellular 
enzymatic superoxide production (Schmidt, Du Yan, Wautier, & Stern, 1999; Wautier, et al., 
2001). Excessive production of ROS by AGEs activates NF-κB and TNFα, which further 
enhances the production of superoxide (J. Kim, Lee, Park, & Yoo, 2010; Roberge, et al., 
2014; Ungvari, et al., 2007). 
 Under hyperglycaemic conditions, a number of biochemically active substances such 
as 3-deoxyglucosone, amadori products, diacylglycerol, methylglyoxal, ROS, AGE and 
nitrosylated species are produced which contribute to and promote diabetes-associated 
endothelial dysfunction (Cristina M Sena, et al., 2012). Thus, oxidative stress seems to be a 
common alteration triggered by hyperglycaemia adjoined by hyperinsulinemia, 
hyperlipidaemia and insulin resistance (Potenza, Gagliardi, Nacci, Carratu, & Montagnani, 
2009). 
8.4 Oxidative stress and endothelial dysfunction  
 Within the vessel wall, oxygen derived radicals like superoxide anions are generated 
by a variety of enzymatic mechanisms. Molecular sources of ROS in the vasculature include 
enzymes of the respiratory chain, specific NADPH oxidase (NOX) complexes, xanthine 
oxidase, uncoupled eNOS, cyclooxygenase, lipoxygenase and cytochromeP450 
monooxygenase (Cai & Harrison, 2000; Ježek & Hlavatá, 2005; Leopold & Loscalzo, 2009; 
Ray & Shah, 2005; Rueckschloss, Duerrschmidt, & Morawietz, 2003; Soccio, Toniato, 
Evangelista, Carluccio, & De Caterina, 2005; Turrens, 2003). NOXs are the only enzyme 
with the primary function of generating ROS (Drummond, Selemidis, Griendling, & Sobey, 
2011; Lassègue, San Martín, & Griendling, 2012). Under normal physiological conditions, 
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the detrimental effects of ROS are counter-balanced by vascular antioxidant enzymes 
including catalases, superoxide dismutases, glutathione peroxidases, 
glutathione S-transferases, glucose-6-phosphate dehydrogenases and heme oxygenase 
(Leopold & Loscalzo, 2009). In a state of oxidative imbalance, excessive production of ROS 
is implicated in the pathogenesis of various diseases including ageing, dementia, 
ischemia-reperfusion injury and atherosclerosis (Madamanchi, Vendrov, & Runge, 2005). 
Thus, increased oxidative stress is another important mechanism of endothelial dysfunctio n in 
diabetes mellitus and associated conditions.  
9. The biguanide anti-hyperglycaemic agent, metformin 
Metformin is an old drug that has been used to treat diabetes for 60 years (Bailey & 
Turner, 1996; Triggle & Ding, 2017). In recent times, it has evolved to be the first line 
pharmacological choice for the treatment of Type 2 diabetes. Metformin is a member of the 
biguanide family of drugs, which include phenformin and buformin. Phenformin and 
buformin, showed a very high risk of severe lactic acidosis events, whilst the risk of lactic 
acidosis with metformin remains low and was probably overstated in its earlier use.  
As for many drugs, the use of metformin has occurred without a full understanding of 
its mechanism of action, but recent investigations provide expanding knowledge in this area. 
Metformin exerts its anti-hyperglycaemic effect in several ways. Metformin primarily lowers 
glucose levels in blood by increasing insulin sensitivity and thus increasing uptake of glucose 
by muscle cells and by reducing production in the liver. New studies investigated the effect of 
metformin on the incretin and GLP1 systems (Zhao, et al., 2015), showing intestinal AMPK 
pathways increasing secretion of GLP1 and related peptides (DeFronzo, et al., 2016). The gut 
directed action is an important component of the anti-hyperglycaemic action of metformin. 
In skeletal muscle, metformin improves the uptake of glucose into cells via activation 
of the solute carriers (SLC2A4) and GLUT4 deployment. Inhibition of complex 1, in the 
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mitochondrial respiratory chain, decreases the ATP/AMP ratio (leading to increased 
activation of AMPK). This action inhibits the production of glucose-6-phosphatase 
dehydrogenase (G6PDH) (mimicking the normal feedback mechanism and reduces the 
production of glucose) and phosphoenolpyruvate carboxykinase (PEPCK). It is the 
interference with glycogenolysis and glycolysis by metformin that leads to the production of 
lactic acid, where tissues are hypoperfused or hypoxic and the rare potential development of 
lactic acidosis (Salpeter, Greyber, Pasternak, & Salpeter, 2003). 
Metformin raises the tissue concentration of hydrogen sulphide (H2S), which is an 
atheroprotective gasotransmitter (Hamidi Shishavan, et al., 2017; Xu, Liu, & Liu, 2014). H2S 
functions as a vasculoprotective factor by sulfhydrating potassium channels and acting as an 
EDHF (Félétou M. , 2011). EDHF-mediated responses are modified in various pathological 
conditions (hypertension, atherosclerosis, hypercholesterolemia, heart fa ilure, ischemia–
reperfusion, angioplasty, eclampsia, diabetes, sepsis) and with aging (Feletou & Vanhoutte, 
2004, 2006). This could be the mechanism for enhanced acetylcholine induced relaxation 
seen when metformin was used (Marfella, et al., 2010).  
Metformin attenuates fluctuating glucose-induced endothelial dysfunction through 
enhancing guanosine 5′-triphosphate cyclohydrolase 1 (GTPCH1) mediated eNOS recoupling 
and inhibiting NADPH oxidase (An, et al., 2016). Endothelial dysfunction, characterised by 
reduced NO bioavailability, is involved in the initiation and progression of the vascular 
complications of diabetes (Davignon & Ganz, 2004; Esper et al, 2006). eNOS is responsible 
for most of the endothelial NO production. GTPCH1 is a rate limiting enzyme to 
produce BH4, and if BH4 production falls then NO production is reduced. 
Currently, G6PDH appears to be the mitochondrial target of action of metformin. 
G6PDH is inhibited by the hyperglycaemia-mediated increase in protein kinase A and is the 
rate limiting step in the pentose phosphate pathway (J. Zhang, et al., 2016). Reduced G6PD 
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activity reduces NADPH levels, the cells’ principal reductant molecule, leading to an increase 
in oxidative stress. Metformin mediated increase in AMPK, will reduce PKA signalling 
through phosphorylation of the CREB cycle, reversing hyperglycaemia induced inhibition of 
G6PDH and reducing oxidative stress (C. H. Lee & Yu, 2016; Triggle & Ding, 2017).  
Triggle et al (Triggle & Ding, 2017) identified a number of endothelium-specific micro 
RNAs as regulators of endothelial function, and linked them to regulation of angiogenesis 
(cell proliferation, aging and apoptosis) and the development of diabetes- induced endothelial 
dysfunction and inflammation (Triggle & Ding, 2017). High glucose increases the levels of 
miR34a in microvascular endothelial cells and this is prevented by metformin (Triggle & 
Ding, 2017). Metformin is therefore thought to have a direct effect on endothelial function 
through antioxidant effects via regulation of eNOS, improved NO production, inhibition of 
mitochondrial complex 1, activation of AMPK and inhibition of apoptosis (Triggle & Ding, 
2017). Regardless of the cell Type, AMPK activation can explain most, if not all of the 
cellular actions of metformin. 
Blood levels of metformin are obviously relevant to the actions of metformin. Importantly, 
metformin is not metabolised in animals or humans and is eliminated intact via renal 
mechanisms (He & Wondisford, 2015). One implication of this metabolic profile is that 
metformin is less sensitive to metabolic drug interactions and interactions arise related to the 
uptake and transport mechanisms that move metformin around the body. The maximum dose 
of metformin orally in humans in most settings is 2.5-3 g per day which equates to 
approximately 35-42 mg/kg (Davoren, 2014; He & Wondisford, 2015). This produces a 
trough steady-state plasma concentration for metformin of between 54 to 4133ng/ml and is 
highly dependent on the individual (Christensen, et al., 2011; Gong, Goswami, Giacomini, 
Altman, & Klein, 2012). The difficulty of recognising therapeutic concentrations of 
metformin has recently been reviewed (Kajbaf, De Broe, & Lalau, 2016). In humans 
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metformin concentrations after passage through the liver are usually in the range of 10 – 40 
µM (He, 2015). 
 
Plasma concentrations of metformin in animal studies are in the range of 10 -70 µM (He & 
Wondisford, 2015; Wilcock & Bailey, 1994). Doses of metformin used in rat studies are 
typically in the range of 100 mg/kg , in excess of doses attainable in human in vivo 
studies(Pournaghi, Sadrkhanlou, Hasanzadeh, & Foroughi, 2012). Palmitic acid induced 
endothelial dysfunction in HUVECS was attenuated by metformin at 0.5-1mM 
concentrations (Ke, et al., 2017). Metformin has been used for in vitro studies at 
concentrations up to 10 mM (Dallaglio, et al., 2014; Little, et al., 2007) which greatly 
exceeds in vivo concentrations and such studies reveal actions of metformin that may be 
interesting but are not clinically or therapeutically relevant. 
10. Metformin and endothelial dysfunction 
Clinical studies of metformin action on hyperglycaemia and associated insulin 
resistance have addressed its effects on endothelial dysfunction. In 2001, Mather et al 
(Mather, Verma, & Anderson, 2001) evaluated the effect of metformin on endothelial 
function in patients with Type 2 diabetes and observed that metformin intake improves 
insulin resistance and endothelium-dependent vasodilation assessed using forearm 
plethysmography; endothelium-independent and nitrate-independent vasodilation remained 
unaffected in these studies. These data indicate that metformin induced insulin sensitivity 
associates with its vasodilatory effects. Since inflammation is a factor in different phases of 
atherosclerosis, long-term treatment (4.3 years) with metformin added to insulin therapy 
attenuates several inflammatory biomarkers of endothelial dysfunction (such as vWF and 
soluble VCAM-1) in patients with Type 2 diabetes, indicating the potential utility of 
metformin in reducing cardiovascular morbidity and mortality (de Jager, et al., 2014). 
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Similarly, in 2005, Vitale et al (Vitale, et al., 2005) examined the effect of metformin (500 
mg, b.i.d, 3 months) on endothelial function in 65 patients with metabolic syndrome and 
observed that metformin treatment improved endothelium-dependent flow-mediated 
dilatation in the brachial artery and insulin resistance (measured by homeostasis model 
assessment- insulin resistance or HOMA-IR), indicating that insulin resistance and endothelial 
dysfunction are interrelated and can be influenced by metformin. Metformin treatment also 
improves flow-mediated dilation in patients with Type 1 diabetes (Pitocco, et al., 2013). The 
REMOVAL trial in Type 1 diabetes showed no benefit in endothelial dysfunction from 
glycaemic control, however, it did indicate benefit in cardiovascular risk (Petrie, et al.). Other 
studies (Jensterle, et al., 2008; Naka, et al., 2011) involving women with polycystic ovary 
syndrome (PCOS) treated with metformin or rosiglitazone, showed that metformin is as 
effective as rosiglitazone in improving flow mediated vasodilation, without affecting 
endothelium-independent relaxation. Metformin treatment is also associated with a decrease 
in HOMA-IR. Metformin treatment for 3 months improves arterial stiffness and associated 
endothelial dysfunction as well as reducing carotid intima media thickness in women with 
PCOS (Agarwal, et al., 2010; Kaya, et al., 2015). There are several clinical trials 
(https://clinicaltrials.gov) addressing the effects of metformin alone (NCT00169624) or in 
combination with other anti-diabetic drugs in patients with Type 2 diabetes (NCT00169624) 
and PCOS (NCT01459445). Therefore, metformin monotherapy or in combination with other 
anti-diabetic strategies represents a useful therapeutic option for targeting the endothelial 
dysfunction which accompanies hyperglycaemia and insulin resistance. The UKDPS data 
from the aggregate of all the studies showed there were fewer diabetes-related endpoints 
(RR 19% [2-33], p=0.033) in the metformin group (UK Prospective Diabetes Study 
(UKPDS) Group, 1998). 
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11. Molecular mechanism(s) of metformin actions in improving endothelial dysfunction 
 11.1 Inhibition of inflammatory response and oxidative stress in endothelial cells  
An earlier study in 2003 showed that metformin (0.1—2.5 µg/ml) inhibited monocyte 
adhesion induced by advanced glycation end-products (AGE) by repressing endothelial cell 
adhesion molecules (Mamputu, Wiernsperger, & Renier, 2003). This pharmacological effects 
was also observed by Hattori et al (Hattori, Suzuki, Hattori, & Kasai, 2006) who showed that 
metformin (2-10 mM), like the AMPK activator AICAR, inhibits endothelial cell 
inflammation via AMPK-dependent inhibition of the IKK/IKBα/NF-KB pathway. The 
consequence of metformin treatment is the inhibition of the TNF-α–induced gene expression 
of VCAM-1, E-selectin, ICAM-1, and MCP1, which contribute to monocyte adhesion to 
activated endothelial cells. Pro-inflammatory cytokines like VCAM1 and MCP1 are also 
repressed by corepressor BCL6, and PARP1 suppresses BCL6 expression by binding to 
intron 1 of BCL6. Metformin (1 mM) up regulates BCL6 expression via AMPK-dependent 
phosphorylation of PARP1 at ser177 (Gongol, et al., 2013), suggesting that metformin could 
be a useful agent in preventing monocyte adhesion to endothelial cells. Additional 
mechanisms of action of metformin include the inhibition of LOX-1 signalling, which is an 
important mediator in endothelial dysfunction and atherosclerosis (Xu, et al., 2013). By 
ameliorating oxLDL-induced LOX-1 expression, metformin (20µM) decreases intracellular 
oxidative stress (Hung, Chan, Chu, Lin, & Tsai, 2016). The anti-oxidative function of 
metformin (10 µM- 1 mM) is also related to inhibition of TRAF3IP2 (Valente, Irimpen, 
Siebenlist, & Chandrasekar, 2014). 
  11.2 Improved NO production and endothelium-dependent vasorelaxation 
eNOS dependent NO production increases endothelium-dependent relaxation. 
Metformin (60mg/kg/d) treatment restores endothelial function in the aorta of STZ-treated 
rats (Type 1 diabetes model) as well as Goto-Kakizaki (GK) rats (Type 2 diabetes model) by 
increasing NO bioavailability and normalizes endothelium-dependent vasorelaxation (C. M. 
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Sena, et al., 2011). In 2006, a landmark study by the Zou group identified that AMPK 
activation by therapeutically relevant concentrations of metformin (50-500μM) increased NO 
production via increasing eNOS phosphorylation and eNOS interaction with HSP90. Of 
clinical relevance, metformin restored impaired eNOS-HSP90 interaction in endothelial cells 
exposed to high glucose levels (Davis, Xie, Viollet, & Zou, 2006). The eNOS activating 
effect of metformin (250 mg/kg/d) has also been demonstrated in endothelial progenitor cells 
from STZ-induced diabetic mice (J. W. Yu, et al., 2016). In agreement with these data, 
metformin (300 mg/kg/d) treatment also increase protein expression of GCH1 (the rate-
limiting enzyme in BH4 biosynthesis) in wild type as well as Ins2 (+/Akita) mice and 
glomerular endothelial cells by slowing down the degradation rate of GCH1, without 
affecting GCH1 gene expression. This suggests that the upregulation of GCH1 by metformin 
occurs through a posttranslational mechanism (Kidokoro, et al., 2013). Metformin (300 
mg/kg/d) mediated upregulation of GCH1 protein expression (but not gene expression) is also 
seen in streptozotocin- induced diabetic mice and high glucose treated human endothelial cells 
by preventing proteasome-mediated GCH1 degradation (S. Wang, Xu, Song, Viollet, & Zou, 
2009). Since metformin induced GCH1 upregulation can be reversed by a dominant negative 
mutant of AMPK (S. Wang, et al., 2009), it is highly possible that AMPK is involved in the 
GCH1 upregulatory effects of metformin. Metformin (100 mg/kg/d) also increases NO 
bioavailability by inhibiting ER stress and ROS generation via AMPK and PPARδ pathways 
(Cheang, et al., 2014). These protective actions contribute to the improved endothelium-
dependent relaxation in mice under diabetic and obese conditions (Cheang, et al., 2014). 
11.3 Inhibition of endothelial senescence and apoptosis 
The senescence and apoptosis of endothelial cells is an important contributor to 
endothelial dysfunction by increasing pro- inflammatory cytokine expression and cell cycle 
arrest. High glucose induces endothelial cell senescence by repressing SIRT1 expression. 
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Metformin (50µM) improves endothelial senescence in high glucose treated endothelial cells 
by increasing SIRT1 expression and activity, thereby repressing high glucose induced 
endothelial cell aging and apoptosis (Arunachalam, Samuel, Marei, Ding, & Triggle, 2014). 
In addition, metformin (50µM) also repressed senescent “memory” induced by high glucose 
through increasing SIRT1 activity (E. Zhang, et al., 2015). Under diabetic conditions, 
excessive high level of blood glucose causes endothelial injury and apoptosis. In this regard, 
metformin (100µM) ameliorates high glucose induced cell death in endothelial cells from 
multiple origins by suppressing mitochondrial permeability transition (Detaille, et al., 2005).  
 11.4 Improved vascular integrity 
Increased vascular permeability causes endothelial leakage and the extravasation of 
monocytes. Metformin (0.1-1 mM) decreases vascular permeability in brain endothelial cells 
via AMPK, suggesting the utility of metformin in preventing the initiating event of 
endothelial dysfunction in endothelial cells (Takata, et al., 2013).  Endothelial glycocalyx is 
an important Type of matrix structure that prevents vascular permeability. Metformin (0.33 
mg/ml) treatment of db/db mice leads to improved glycocalyx barrier function and prevents 
edema in the heart and kidney of the mice (Eskens, Zuurbier, van Haare, Vink, & van 
Teeffelen, 2013). Metformin (5mM for in vitro studies, and 400mg/kg bid for in vivo studies) 
decreases permeability in endothelial cells stimulated with high glucose and LPS as well as 
improving lung barrier integrity in both STZ-induced diabetic and db/db mice models; the 
mechanism is linked to the activation of the LKB1/AMPK pathway (Y. Yang, et al., 2017).  
12. New mechanistic insights into the actions of metformin in cardiovascular and other 
systems 
 
12.1 Epigenetic effects of metformin  
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Emerging evidence has shown that metformin also has epigenetic functions, which has been 
reviewed elsewhere recently (Bridgeman, Ellison, Melton, Newsholme, & Mamotte, 2018). 
Metformin can influence the activation of multiple epigenetic modifiers, mostly via AMPK, 
since AMPK can phosphorylate multiple substrates, including histone acetyltransferases, 
class II histone deacetylases (HDACs) and DNA/histone methyltransferases, thus leading to 
their inhibition; Metformin can also increase SIRT1 activity and protect against high glucose 
induced "memory" in endothelial cells (E. Zhang, et al., 2015). In addition, Metformin delays 
endothelial senescence via AMPK-dependent upregulation of histone methyltransferse 
DOTL1, thereby increasing binding of H3K79me3 to SIRT3 gene promoter (Karnewar, et al., 
2018). These epigenetic effects of metformin underlies its broad regulatory effects on gene 
expression. More recently, Chen et al (Y. C. Chen, et al., 2018) have shown that metformin 
(1-50 µM) has anti- inflammatory effects by reducing the expression IP-10, MCP-1 and NF-
kB phosphorylation in LPS-stimulated THP1 cells. Furthermore, the authors observed that 
metformin reduces IL-10 expression by reducing the binding of global acetylated histones H3 
and H4 to IP-10 gene promoter in LPS-stimulated THP-1 cell. In another study by Tang et al. 
(Tang, et al., 2018), Metformin (2.5-10 mM) has been reported to inhibit the  proliferation 
and migration, and promotes apoptosis of ovarian cancer cells by increasing AMPK 
phosphorylation, and reducing PRC2 components expression and associated H3K27 
trimethylation. Moreover, EZH2 overexpression abrogated the anti-cancer effect 
of metformin. This epigenetic effect of metformin is AMPK-dependent, since AMPK 
inhibition by Compound C, abolishes the effect of metformin on reducing H3K27me3. In 
light of recently evidence showing atherogenic role of PRC2 component EZH2 (Lv, et al., 
2016; Xiaoling, et al., 2016) and associated H3K27me3 (Xu, et al., 2018) in atherosclerosis, 
it will be of interest whether metformin reduces PCR2 components and activity in endothelial 
cells. Further research into this area will reveal a novel mode of action for metformin and 
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raises the possibility that metformin may be exploited as epigenetic drug that could affect 
atherogenic processes, including endothelial dysfunction.  
12.2. Metformin on autophagy 
 
Decreased AMPK activity and associated defective autophagy is associated with 
atherosclerosis. After incubating with in high glucose (25 mM) and subsequently with 0.4 
mM palmitate, human aortic endothelial cells displayed decreased AMPK activation, 
impaired autophagy and are prone to apoptosis and enhanced monocyte adhesion to 
endothelial cells. These effects are reversed by autophagy activator rapamycin and AMPK 
activators (AICAR, A769662, and phenformin). This study suggests that AMPK activation 
could prevent glucose and palmitate induced AMPK uncoupling from autophagy in 
endothelial cells (Weikel, Cacicedo, Ruderman, & Ido, 2015). In vivo, administration of 
metformin (250 mg/kg/d) in ApoE-/- mice lead to significant reduction and stabilization of 
atherosclerotic plaques, associated with increased content of smooth muscle cells, and 
collagen, as well as reduced content of macrophages (Michiels, Apers, De Meyer, & 
Martinet, 2016). Metformin treatment also induce autophagy by reducing SQSTM1/p62 and 
increasing GFP-LC3 cleavage into free GFP in GFP-LC3 transgenic mice. In cultured 
endothelial cells, 2 days treatment of metformin (10 mM) attenuates monocyte adhesion to 
TNFa-activated endothelial cells via repressing ICAM1 and VCAM1. However, metformin 
mediated protective effects was reversed by autophagy inhibition using Atg7 siRNA-
mediated depletion (Michiels, et al., 2016). It remains to be clarified whether AMPK is 
involved in metformin mediated autophagy induction in endothelial cells.  
12.3. Metformin on endothelial cell metabolism 
 
Recently, endothelial cell metabolism (such as glucose, fatty acid, lipid etc) has been shown 
to be critical for maintaining metabolic health. In 1996, Sasson et al. (Sasson, et al., 1996) 
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showed that metformin (1-5 mM) regulates hexose transport in both bovine endothelial cells 
and smooth muscle cells. Glucose-starvation induces ER stress in mouse microvascular 
endothelial cells, after treatment with metformin (50 μM and 2 mM), glucose-starvation 
induced ER stress, was revered. This pharmacological action is exerted through an AMPK-
independent mechanism (Samuel, et al., 2017).  
12.4. Metformin on other kinases and transcriptional factors 
 
LKB1 is one of the upstream kinase of AMPK. Metformin (1 mM) increased the LKB1 
phosphorylation at Ser428 and its subsequent nuclear export into the cytosols, and increases 
AMPK/LKB1 association in ECs (Xie, Dong, Scholz, Neumann, & Zou, 2008). In addition, 
Metformin has been shown to influence other kinase activity. For example, Metformin (500 
µM) protects against free fatty acid (palmitate) induced endothelial apoptosis and 
dysfunction, partially by reducing p38 MAPK phosphorylation. This inhibitory effects of 
metformin on p38 is AMPK-dependent, since AMPK inhibition by compound C reverses the 
p38 inhibiting effects of metformin (Eriksson & Nystrom, 2014). Metformin (1 mM) also 
inhibits basal as well as VEGF-induced phosphorylation of ERK1/2 in an AMPK-dependent 
manner (Dallaglio, et al., 2014).  
Metformin also modulate gene expression via affecting multiple transcriptional factors, such 
as PPARδ, carbohydrate response element-binding protein (ChREBP), forkhead box O1 
(FOXO1), p53, and NF-kB (Hattori, et al., 2006). Specifically, PPARδ is critical for 
metformin mediated protective effects against ER stress, oxidative stress, and high fat-diet 
induced endothelial dysfunction (Cheang, et al., 2014). In endothelial cells, Metformin (1-2 
mM) also decreases high glucose- induced upregulation of TXNIP by reducing the nuclear 
transport of ChREBP and FOXO1, and their binding to TXNIP promoter. This effect was 
reversed by AMPK inhibitor compound C, indicating that metformin impacts ChREBP and 
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FOXO1 in an AMPK-dependent manner (X. Li, et al., 2015). Metformin (2-10 mM) also 
dose-dependently inhibits TNFα induced NF-kB (p65 and p50 subunit) activation in 
HUVECs, which was reversed by AMPK siRNA, indicating an AMPK-dependent anti-
inflammatory effects (Hattori, et al., 2006). In addition, Metformin (50 µM) modulates 
hyperglycaemia- induced endothelial senescence and apoptosis through SIRT1 (Arunachalam, 
et al., 2014), thereby reducing FOXO1) and p53 acetylation, and decreasing high glucose-
induced premature senescence in endothelial cells. 
 
13. Conclusions and future directions 
Hyperglycaemia has deleterious effects on the cardiovascular system mostly the 
vascular system where it is the cause of microvascular disease and is strongly associated with 
the occurrence of macrovascular disease. The deleterious biochemical mechanisms of 
hyperglycaemia are not completely understood at a molecular level but they are probably 
related to the phenomenon of insulin resistance. Metformin improves insulin resistance and 
therefore has an anti-hyperglycaemic and insulin- lowering action in patients with Type 2 
diabetes. Metformin also has additional actions in the same way as the lipid lowering statins 
have favourable pleiotropic, anti- inflammatory and anti-oxidative effects on the vasculature 
beyond their lipid lowering actions. The main effect of metformin is on ED where the 
integrity of the endothelium is a critical and long-term determinant of vascular health and 
thus of the occurrence of CVD. We have reviewed the causes of ED and outlined the effects 
of metformin to improve or to prevent deterioration of ED which potentially leads to reduced 
CVD in patients with Type 2 diabetes and potentially other settings in which the use of 
metformin is being proposed. Metformin has a very simple chemical structure. The dose of 
metformin is relatively high and to some extent its actions might be considered alongside that 
of nutrients. The simple structure means that it is unlikely that it will be possible to develop 
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new agents with similar or better properties and mechanisms of action so the future relies on 
fully exploiting the pharmacokinetics, pharmacodynamics and therapeutic targeting to 
achieve the full therapeutic potential of metformin. This approach has recently been 
demonstrated by the description of the delayed release metformin product which acts in the 
distal gut and reveals a gut hormone-dependent anti-hyperglycaemic action of metformin 
Several important classes of drugs for the treatment of hyperglycaemia have shown in large 
scale use to display serious unwanted effects such as the bone fractures and heart failure 
associated with glitazones and the recent signs of the occurrence of amputations of digits 
associated with the use of some SGLT2 inhibitors (S. Lee, 2017; Wu, Ding, Tanaka, & 
Zhang, 2014). There does not appear to be a hidden unwanted effects profile for, metformin 
so it has the potential to provide a really effective and safe future in the treatment of 
hyperglycaemia and especially for its favourable CVD effects including beneficial effects on 
ED. 
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Figure 1 
Role of metformin in endothelial dysfunction 
Metformin improves endothelial dysfunction via the following aspects: (1) inhibiting 
leukocyte adhesion; (2) increase nitric oxide production and inhibiting eNOS uncoupling; (3) 
inhibiting vascular aging; (4) prevent endothelial cell injury and apoptosis. The 
pharmacological effects of metformin were exerted through LKB1/AMPK and other targets. 
Abbreviations: NF-kB, nuclear factor kappa B; ICAM1, intracellular adhesion molecule 1; 
VCAM1, vascular adhesion molecule 1; MCP1, monocyte chemo attractant protein 1; Bcl6, 
B-cell lymphoma 6; PAPP1-p, phosphorylation of poly-ADP-ribose polymerase 1; LOX-1, 
lectin- like oxidized LDL receptor 1; TRAF3IP2, TRAF3 interacting protein 2; NOX, 
NADPH oxidase; ROS, reactive oxygen species; Mn-SOD, manganese superoxide dismutase; 
AGE, advanced glycation end-products; eNOS, endothelial nitric oxide synthase; eNOS-p, 
phosphorylation of eNOS; HSP90, heat shock protein 90; GCH1, GTP cyclohydrolase I; 
BH4, tetrahydrobiopterin; PPARδ, peroxisome proliferator-activated receptor δ; PGC1α, 
PPARgamma Coactivator 1alpha; ER, endoplasmic reticulum; mTOR, the mammalian target 
of rapamycin; Sirt1, Sirtuin 1, mPTP, mitochondrial permeability transition pore. 
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Figure 1.  
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Table. 1. Products modulating the state of the vascular endothelium. 
 
 
Vasodilators    NO (Ignarro, et al., 1987; R MoJ Palmer, et al., 1987)   
 PGI2 (Egan & FitzGerald, 2006; Moncada, et al., 1976)  
 Bradykinin (Drexler, 1998), 
 EDHF (Davignon & Ganz, 2004; Félétou & Vanhoutte, 
2006b; Garland, Hiley, & Dora, 2011) 
 Serotonin  
 Histamine 
Vasoconstrictors  ET-1 (Yanagisawa, et al., 1988),  
 ThromoboxaneA2 
 AngiotensinII 
 Arachidonic acid 
 ProstaglandinH2 
 Thrombin 
 ROS  
Adhesions molecules  ICAM 
 VCAM 
 Endothelial cell adhesion molecule 
Anticoagulants / 
Antithromobotic factors 
 PAI-1(Kruithof, Nicolosa, & Bachmann, 1987), 
 t-PA 
 Thromobodulin, 
  u –PA (Libby, Aikawa, & Jain, 2006) 
Inhibitors  Bradykinin  
 heparin sulphate 
 Transforming growth factor – beta (TGFβ) 
Promoters  Platelet derived growth factor  
 fibroblast growth factor 
 insulin like growth factor 
 ET-1 
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Table 2. Factors mediating and impacting on endothelial dysfunction. 
Notorious stimuli Molecular changes leading to endothelial   dysfunction 
Hypercholesterolemia  
 
 Reduced endothelium dependent vasorelaxation (C. Sena, et al., 
2008).  
 Up regulation of NOX and ROS reducing the bioavailability of 
NO,  eNOS uncoupling (Böger, et al., 2004; Speer, et al., 2014).   
Insulin resistance  
 
 Increased production of ROS by NOX(J. Du, Fan, Mai, & Li, 
2013) 
 over-expression of  PKCβ and induction of  ET-1 expression in 
endothelium (Q. Li, et al., 2013) (Tabit, et al., 2012) 
 increased insulin receptor substrate 
 Phosphorylation at Ser 307 (Nemoto, Kobayashi, Taguchi, 
Matsumoto, & Kamata, 2011)  
 Up regulation of transcription factor forkhead boxO-1 FOXO-
1(Karki, et al., 2015).    
Diabetes  
 
 Induced endothelial dysfunction  
 Advanced end glycation product (AGE) 
 ROS (Paneni, Beckman, Creager, & Cosentino, 2013). 
Pro inflammatory 
factors 
 
 Overexpression of TNFα and IL-1 which promotes leukocyte 
adherence and migration (Barton, 2013) 
 Inflammatory cytokines induced endothelial cells express 
VCAM, ICAM, MCP1, IL6, P-selectin and E –selectin and 
exacerbate the ED (Blake & Ridker, 2001)   
 C- reactive protein directly affects NO bioavailability acting 
through lectin like oxidised LDL receptor-1 which plays pivotal 
role in oxLDL-induced ED in endothelial cells (L. Li, 
Roumeliotis, Sawamura, & Renier, 2004).  
Hypertension  
 
 Reduced NO availability in response to endothelium dependent 
stimuli  in hypertension is attributed to higher levels of ADMA 
(Sasser, Cunningham, & Baylis, 2014).  
Ageing 
 
 Aging results in diminished  production of NO due  
o Increased activity of arginase competing with eNOS for 
common substrate arginine (Santhanam, et al., 2007) 
o Reduced expression and activity of eNOS (Lesniewski, et 
al., 2011)  
o Decrease release of prostanide (Gano, et al., 2014) 
o Increase release of ET-1.   
Hemodynamic Forces   Low sheer stress modulates gene expression through 
mechanoreception and mechanotransduction resulting in altered   
atherogenic endothelial phenoytype and formation of 
atherosclerotic plaque (Pahakis, Kosky, Dull, & Tarbell, 2007)  
 Suppression of NO and prostacyclin, augmentation of ET-1, lipid 
uptake and its catabolism induce plaque inflammation and 
oxidation in endothelial cells (White, et al., 2011)  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Environmental 
factors  
 
 Processes in smoking induce atherogenesis, endothelial 
dysfunction and damage, 
 Induction of inflammation, increase in oxidation of 
proatherogenic lipids and shift towards procoagulant state in 
circulation (Messner & Bernhard, 2014)  
Psychological stress  Sleep deprivation decrease eNOS and cGMP levels indicating 
damaged eNOS/NO/cGMP / pathway(J. Jiang, et al., 2017). 
Diet  
 
 High salt intake results in blunted endothelium dependent 
vasodilation (Beyer, et al., 2014). 
Oxidative Stress 
(H2O2) 
 
 Super oxide anions scavenge NO and form peroxynitrate 
resulting in reduced bioavailability of  NO (Montezano & Touyz, 
2012) . 
 ROS cause S-glutathionylation of eNOS and render it inactive 
(Y. Zhang, Janssens, Wingler, Schmidt, & Moens, 2011) 
Infectious Agents 
(e.g., bacteria l 
endotoxins, viruses) 
 
 Infectious agents such as hepatitis A virus, herpes simplex virus-
1, cytomegalovirus and bacteria (Helicobactor  pylori,and 
Chlamydia pneumonia) are reported to be associated  with 
coronary artery disease 
Life style (sedentary)  Cardiac patients with lower physical activity levels exhibits ED 
manifested by reduced flow mediated vasodilation (Luk, et al., 
2012)  
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